FAP and neoplasm: To our knowledge, this work is the first to use anti-FAP NIR-PIT to deplete CAFs in the TME as well as in spontaneously developed MMTV-PyVT mammary tumors, which more closely mimic the human TME, including cellular and spatial heterogeneity, tumor growth, and CAF subsets [49].